

Ulrich Krafft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526181/publications.pdf>

Version: 2024-02-01

11
papers

171
citations

1306789

7
h-index

1372195

10
g-index

12
all docs

12
docs citations

12
times ranked

272
citing authors

#	ARTICLE	IF	CITATIONS
1	Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer: A Retrospective Analysis of a Single-Centre Cohort. <i>Urologia Internationalis</i> , 2022, 106, 638-643.	0.6	0
2	Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma. <i>Biomedicines</i> , 2022, 10, 698.	1.4	4
3	A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer. <i>Laboratory Investigation</i> , 2021, 101, 1281-1288.	1.7	10
4	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 2548.	1.7	17
5	High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 385-389.	3.3	41
6	Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 253-261.	0.9	4
7	Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. <i>Diagnostics</i> , 2020, 10, 864.	1.3	6
8	Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 810.e7-810.e15.	0.8	22
9	Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. <i>Disease Markers</i> , 2018, 2018, 1-21.	0.6	38
10	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 101, 65-73.	0.6	12
11	Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. <i>Pathology International</i> , 2017, 67, 597-601.	0.6	17